Gilead's New HIV Drug Gains U.S. Support and FDA Approval
The U.S. announced support for lenacapavir, a groundbreaking HIV prevention drug requiring only biannual injections, aiming to reach 2 million people by 2028 and significantly impact the global HIV epidemic, especially in low- and middle-income countries.